Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
This report elaborates on the current development of the Neoantigen Cancer Vaccine industry thoroughly based on the international market dynamics and China's market situation.
For a start, the report provides an in-depth analysis of the current market situation through three different aspects - by region, by type and by application, which includes market distribution of different types and applications, import and export analysis of major regions, development trends of different types of products in each region, market opportunities and market restrains of different applications.
Secondly, this report lists the major players in the industry, displaying their market positions and strengths and weaknesses of their products, picturing the current competitive situation of the whole market.
Last but not least, the report analyzes and predicts the investment prospects and risks in the industry on the basis of industry data, combined with experts' opinions and suggestions.
By Player:
Geneos Therapeutics
Roche
Gritstone Oncology
Vaccibody
Merck
Genocea
Brightpath Biotherapeutics
Agenus
Medigene
Advaxis
OSE Immunotherapeutics
Nouscom
By Type:
Off-the-shelf Neovaccines
Personalized Vaccine
By Application:
Hospital
Clinic
Others
By Research Region:
-
North China
-
Central China
-
South China
-
East China
-
Northeast China
-
Southwest China
-
Northwest China
TABLE OF CONTENT
Chapter 1 China Neoantigen Cancer Vaccine Market Overview 2018-2029
-
1.1 China Neoantigen Cancer Vaccine Industry Development Overview
-
1.2 China Neoantigen Cancer Vaccine Industry Development History
-
1.3 China Neoantigen Cancer Vaccine Industry Market Size (2018-2029)
-
1.4 China Neoantigen Cancer Vaccine Market Analysis by Type from Production Side
-
1.4.1 China Neoantigen Cancer Vaccine Production Volume, Production Value and Growth Rate of Off-the-shelf Neovaccines (2018-2029)
-
1.4.2 China Neoantigen Cancer Vaccine Production Volume, Production Value and Growth Rate of Personalized Vaccine (2018-2029)
-
1.5 China Neoantigen Cancer Vaccine Market Analysis by Application from Consumption End
-
1.5.1 China Neoantigen Cancer Vaccine Sales Volume, Sales Value and Growth Rate of Hospital (2018-2029)
-
1.5.2 China Neoantigen Cancer Vaccine Sales Volume, Sales Value and Growth Rate of Clinic (2018-2029)
-
1.5.3 China Neoantigen Cancer Vaccine Sales Volume, Sales Value and Growth Rate of Others (2018-2029)
-
1.6 China Neoantigen Cancer Vaccine Market Analysis by Region
-
1.6.1 North China Neoantigen Cancer Vaccine Market Size and Growth Rate from 2018-2029
-
1.6.2 Central China Neoantigen Cancer Vaccine Market Size and Growth Rate from 2018-2029
-
1.6.3 South China Neoantigen Cancer Vaccine Market Size and Growth Rate from 2018-2029
-
1.6.4 East China Neoantigen Cancer Vaccine Market Size and Growth Rate from 2018-2029
-
1.6.5 Northeast China Neoantigen Cancer Vaccine Market Size and Growth Rate from 2018-2029
-
1.6.6 Southwest China Neoantigen Cancer Vaccine Market Size and Growth Rate from 2018-2029
-
1.6.7 Northwest China Neoantigen Cancer Vaccine Market Size and Growth Rate from 2018-2029
Chapter 2 China Neoantigen Cancer Vaccine Industry Development Environment
-
2.1 Industry Development Environment Analysis
-
2.1.1 Industry Technological Progress Analysis
-
2.1.2 Industrial Organizational Innovation Analysis
-
2.1.3 Changes in Social Habits
-
2.1.4 Alterations in Government Policies
-
2.1.5 Impact of Economic Globalization
-
2.2 Domestic and Foreign Industry Competition Analysis
-
2.2.1 Comparative Analysis on Neoantigen Cancer Vaccine Market Status and Competition at home and abroad in 2023
-
2.2.2 China Neoantigen Cancer Vaccine Market Status and Competition Analysis in 2023
-
2.2.3 China Neoantigen Cancer Vaccine Market Concentration Analysis in 2023
-
2.3 Problems and Countermeasures in the development of China Neoantigen Cancer Vaccine Industry
-
2.3.1 Industry Development Constraints
-
2.3.2 Industry Development Considerations
-
2.3.3 Suggestions on Industry Development Measures
-
2.3.4 Development Strategies for SMEs
-
2.4 Influence of COVID-19 Outbreak on Neoantigen Cancer Vaccine Industry Development
Chapter 3 Neoantigen Cancer VaccineIndustry Chain Analysis
-
3.1 Neoantigen Cancer Vaccine Industry Chain
-
3.2 Neoantigen Cancer Vaccine Upstream Industry Analysis
-
3.2.1 Upstream Industry Development Status
-
3.2.2 Upstream Industry Development Forecast
-
3.2.3 Impact of Upstream Industry on the Neoantigen Cancer Vaccine Market
-
3.3 Neoantigen Cancer Vaccine Downstream Industry Analysis
-
3.3.1 Downstream Industry Development Status
-
3.3.2 Downstream Industry Development Forecast
-
3.3.3 Impact of Downstream Industry on the Neoantigen Cancer Vaccine Market
Chapter 4 China Neoantigen Cancer Vaccine Market, by Type
-
4.1 China Neoantigen Cancer Vaccine Market Trend, by Type
-
4.2 Product Types of Major Suppliers
-
4.3 Competitive Landscape of Major Types
-
4.4 China Neoantigen Cancer Vaccine Total Production Volume and Growth Rate from Production Side
-
4.5 China Neoantigen Cancer Vaccine Production Volume and Growth Rate, by Type
-
4.5.1 China Neoantigen Cancer Vaccine Production Volume and Growth Rate of Off-the-shelf Neovaccines
-
4.5.2 China Neoantigen Cancer Vaccine Production Volume and Growth Rate of Personalized Vaccine
Chapter 5 China Neoantigen Cancer Vaccine Market, by Application
-
5.1 Downstream Market Overview
-
5.2 Competitive Landscape of Major Applications
-
5.3 Market Potential Analysis, by Application
-
5.4 China Neoantigen Cancer Vaccine Total Market Size and Growth Rate from Consumption End
-
5.5 China Neoantigen Cancer Vaccine Market Size and Growth Rate, by Application
-
5.5.1 China Neoantigen Cancer Vaccine Market Size and Growth Rate of Hospital
-
5.5.2 China Neoantigen Cancer Vaccine Market Size and Growth Rate of Clinic
-
5.5.3 China Neoantigen Cancer Vaccine Market Size and Growth Rate of Others
Chapter 6 China Neoantigen Cancer Vaccine Market, by Region
-
6.1 China Neoantigen Cancer Vaccine Production Volume and Production Value, by Region
-
6.2 China Neoantigen Cancer Vaccine Sales Volume and Sales Value, by Region
Chapter 7 North China Neoantigen Cancer Vaccine Market Analysis
-
7.1 North China Neoantigen Cancer Vaccine Market, by Type
-
7.2 North China Neoantigen Cancer Vaccine Market, by Application
Chapter 8 Central China Neoantigen Cancer Vaccine Market Analysis
-
8.1 Central China Neoantigen Cancer Vaccine Market, by Type
-
8.2 Central China Neoantigen Cancer Vaccine Market, by Application
Chapter 9 South China Neoantigen Cancer Vaccine Market Analysis
-
9.1 South China Neoantigen Cancer Vaccine Market, by Type
-
9.2 South China Neoantigen Cancer Vaccine Market, by Application
Chapter 10 East China Neoantigen Cancer Vaccine Market Analysis
-
10.1 East China Neoantigen Cancer Vaccine Market, by Type
-
10.2 East China Neoantigen Cancer Vaccine Market, by Application
Chapter 11 Northeast China Neoantigen Cancer Vaccine Market Analysis
-
11.1 Northeast China Neoantigen Cancer Vaccine Market, by Type
-
11.2 Northeast China Neoantigen Cancer Vaccine Market, by Application
Chapter 12 Southwest China Neoantigen Cancer Vaccine Market Analysis
-
12.1 Southwest China Neoantigen Cancer Vaccine Market, by Type
-
12.2 Southwest China Neoantigen Cancer Vaccine Market, by Application
Chapter 13 Northwest China Neoantigen Cancer Vaccine Market Analysis
-
13.1 Northwest China Neoantigen Cancer Vaccine Market, by Type
-
13.2 Northwest China Neoantigen Cancer Vaccine Market, by Application
Chapter 14 Company Profiles
-
14.1 Geneos Therapeutics
-
14.1.1 Geneos Therapeutics Company Profile
-
14.1.2 Geneos Therapeutics Neoantigen Cancer Vaccine Market Performance
-
14.1.3 Product&Service Introduction
-
14.2 Roche
-
14.2.1 Roche Company Profile
-
14.2.2 Roche Neoantigen Cancer Vaccine Market Performance
-
14.2.3 Product&Service Introduction
-
14.3 Gritstone Oncology
-
14.3.1 Gritstone Oncology Company Profile
-
14.3.2 Gritstone Oncology Neoantigen Cancer Vaccine Market Performance
-
14.3.3 Product&Service Introduction
-
14.4 Vaccibody
-
14.4.1 Vaccibody Company Profile
-
14.4.2 Vaccibody Neoantigen Cancer Vaccine Market Performance
-
14.4.3 Product&Service Introduction
-
14.5 Merck
-
14.5.1 Merck Company Profile
-
14.5.2 Merck Neoantigen Cancer Vaccine Market Performance
-
14.5.3 Product&Service Introduction
-
14.6 Genocea
-
14.6.1 Genocea Company Profile
-
14.6.2 Genocea Neoantigen Cancer Vaccine Market Performance
-
14.6.3 Product&Service Introduction
-
14.7 Brightpath Biotherapeutics
-
14.7.1 Brightpath Biotherapeutics Company Profile
-
14.7.2 Brightpath Biotherapeutics Neoantigen Cancer Vaccine Market Performance
-
14.7.3 Product&Service Introduction
-
14.8 Agenus
-
14.8.1 Agenus Company Profile
-
14.8.2 Agenus Neoantigen Cancer Vaccine Market Performance
-
14.8.3 Product&Service Introduction
-
14.9 Medigene
-
14.9.1 Medigene Company Profile
-
14.9.2 Medigene Neoantigen Cancer Vaccine Market Performance
-
14.9.3 Product&Service Introduction
-
14.10 Advaxis
-
14.10.1 Advaxis Company Profile
-
14.10.2 Advaxis Neoantigen Cancer Vaccine Market Performance
-
14.10.3 Product&Service Introduction
-
14.11 OSE Immunotherapeutics
-
14.11.1 OSE Immunotherapeutics Company Profile
-
14.11.2 OSE Immunotherapeutics Neoantigen Cancer Vaccine Market Performance
-
14.11.3 Product&Service Introduction
-
14.12 Nouscom
-
14.12.1 Nouscom Company Profile
-
14.12.2 Nouscom Neoantigen Cancer Vaccine Market Performance
-
14.12.3 Product&Service Introduction
Chapter 15 Research Conclusions and Investment Suggestions
-
15.1 Neoantigen Cancer Vaccine Industry Research Conclusions
-
15.2 Neoantigen Cancer Vaccine Industry Investment Suggestions
-
15.2.1 Suggestions on Industry Development Strategy
-
15.2.2 Suggestions on Industry Investment Direction
-
15.2.3 Suggestions on Industry Investment Strategy
List of Tables and Figures
-
Figure China Neoantigen Cancer Vaccine Industry Market Size (2018-2029)
-
Figure China Neoantigen Cancer Vaccine Production Volume, Production Value and Growth Rate of Off-the-shelf Neovaccines (2018-2029)
-
Figure China Neoantigen Cancer Vaccine Production Volume, Production Value and Growth Rate of Personalized Vaccine (2018-2029)
-
Figure China Neoantigen Cancer Vaccine Sales Volume, Sales Value and Growth Rate of Hospital (2018-2029)
-
Figure China Neoantigen Cancer Vaccine Sales Volume, Sales Value and Growth Rate of Clinic (2018-2029)
-
Figure China Neoantigen Cancer Vaccine Sales Volume, Sales Value and Growth Rate of Others (2018-2029)
-
Figure North China Neoantigen Cancer Vaccine Market Size and Growth Rate from 2018-2029
-
Figure Central China Neoantigen Cancer Vaccine Market Size and Growth Rate from 2018-2029
-
Figure South China Neoantigen Cancer Vaccine Market Size and Growth Rate from 2018-2029
-
Figure East China Neoantigen Cancer Vaccine Market Size and Growth Rate from 2018-2029
-
Figure Northeast China Neoantigen Cancer Vaccine Market Size and Growth Rate from 2018-2029
-
Figure Southwest China Neoantigen Cancer Vaccine Market Size and Growth Rate from 2018-2029
-
Figure Northwest China Neoantigen Cancer Vaccine Market Size and Growth Rate from 2018-2029
-
Figure Neoantigen Cancer Vaccine Industry Chain
-
Table Product Types of Major Suppliers in 2023
-
Figure China Neoantigen Cancer Vaccine Market Share by Type in 2018
-
Figure China Neoantigen Cancer Vaccine Market Share by Type in 2023
-
Figure China Neoantigen Cancer Vaccine Total Production Volume and Growth Rate from Production Side (2018-2023)
-
Figure China Neoantigen Cancer Vaccine Production Volume and Growth Rate of Off-the-shelf Neovaccines (2018-2023)
-
Figure China Neoantigen Cancer Vaccine Production Volume and Growth Rate of Personalized Vaccine (2018-2023)
-
Figure China Neoantigen Cancer Vaccine Market Share by Application in 2018
-
Figure China Neoantigen Cancer Vaccine Market Share by Application in 2023
-
Figure China Neoantigen Cancer Vaccine Total Market Size and Growth Rate from Consumption End
-
Figure China Neoantigen Cancer Vaccine Market Size and Growth Rate of Hospital (2018-2023)
-
Figure China Neoantigen Cancer Vaccine Market Size and Growth Rate of Clinic (2018-2023)
-
Figure China Neoantigen Cancer Vaccine Market Size and Growth Rate of Others (2018-2023)
-
Table China Neoantigen Cancer Vaccine Production Volume by Region (2018-2023)
-
Table China Neoantigen Cancer Vaccine Production Volume Share by Region (2018-2023)
-
Figure China Neoantigen Cancer Vaccine Production Volume Share by Region (2018-2023)
-
Table China Neoantigen Cancer Vaccine Production Value by Region (2018-2023)
-
Table China Neoantigen Cancer Vaccine Production Value Share by Region (2018-2023)
-
Figure China Neoantigen Cancer Vaccine Production Value Share by Region (2018-2023)
-
Table China Neoantigen Cancer Vaccine Sales Volume by Region (2018-2023)
-
Table China Neoantigen Cancer Vaccine Sales Volume Share by Region (2018-2023)
-
Figure China Neoantigen Cancer Vaccine Sales Volume Share by Region (2018-2023)
-
Table China Neoantigen Cancer Vaccine Sales Value by Region (2018-2023)
-
Table China Neoantigen Cancer Vaccine Sales Value Share by Region (2018-2023)
-
Figure China Neoantigen Cancer Vaccine Sales Value Share by Region (2018-2023)
-
Table North China Neoantigen Cancer Vaccine Production Volume by Type (2018-2023)
-
Table North China Neoantigen Cancer Vaccine Production Volume Share by Type (2018-2023)
-
Figure North China Neoantigen Cancer Vaccine Production Volume Share by Type (2018-2023)
-
Table North China Neoantigen Cancer Vaccine Sales Volume by Application (2018-2023)
-
Table North China Neoantigen Cancer Vaccine Sales Volume Share by Application (2018-2023)
-
Figure North China Neoantigen Cancer Vaccine Sales Volume Share by Application (2018-2023)
-
Table Central China Neoantigen Cancer Vaccine Production Volume by Type (2018-2023)
-
Table Central China Neoantigen Cancer Vaccine Production Volume Share by Type (2018-2023)
-
Figure Central China Neoantigen Cancer Vaccine Production Volume Share by Type (2018-2023)
-
Table Central China Neoantigen Cancer Vaccine Sales Volume by Application (2018-2023)
-
Table Central China Neoantigen Cancer Vaccine Sales Volume Share by Application (2018-2023)
-
Figure Central China Neoantigen Cancer Vaccine Sales Volume Share by Application (2018-2023)
-
Table South China Neoantigen Cancer Vaccine Production Volume by Type (2018-2023)
-
Table South China Neoantigen Cancer Vaccine Production Volume Share by Type (2018-2023)
-
Figure South China Neoantigen Cancer Vaccine Production Volume Share by Type (2018-2023)
-
Table South China Neoantigen Cancer Vaccine Sales Volume by Application (2018-2023)
-
Table South China Neoantigen Cancer Vaccine Sales Volume Share by Application (2018-2023)
-
Figure South China Neoantigen Cancer Vaccine Sales Volume Share by Application (2018-2023)
-
Table East China Neoantigen Cancer Vaccine Production Volume by Type (2018-2023)
-
Table East China Neoantigen Cancer Vaccine Production Volume Share by Type (2018-2023)
-
Figure East China Neoantigen Cancer Vaccine Production Volume Share by Type (2018-2023)
-
Table East China Neoantigen Cancer Vaccine Sales Volume by Application (2018-2023)
-
Table East China Neoantigen Cancer Vaccine Sales Volume Share by Application (2018-2023)
-
Figure East China Neoantigen Cancer Vaccine Sales Volume Share by Application (2018-2023)
-
Table Northeast China Neoantigen Cancer Vaccine Production Volume by Type (2018-2023)
-
Table Northeast China Neoantigen Cancer Vaccine Production Volume Share by Type (2018-2023)
-
Figure Northeast China Neoantigen Cancer Vaccine Production Volume Share by Type (2018-2023)
-
Table Northeast China Neoantigen Cancer Vaccine Sales Volume by Application (2018-2023)
-
Table Northeast China Neoantigen Cancer Vaccine Sales Volume Share by Application (2018-2023)
-
Figure Northeast China Neoantigen Cancer Vaccine Sales Volume Share by Application (2018-2023)
-
Table Southwest China Neoantigen Cancer Vaccine Production Volume by Type (2018-2023)
-
Table Southwest China Neoantigen Cancer Vaccine Production Volume Share by Type (2018-2023)
-
Figure Southwest China Neoantigen Cancer Vaccine Production Volume Share by Type (2018-2023)
-
Table Southwest China Neoantigen Cancer Vaccine Sales Volume by Application (2018-2023)
-
Table Southwest China Neoantigen Cancer Vaccine Sales Volume Share by Application (2018-2023)
-
Figure Southwest China Neoantigen Cancer Vaccine Sales Volume Share by Application (2018-2023)
-
Table Northwest China Neoantigen Cancer Vaccine Production Volume by Type (2018-2023)
-
Table Northwest China Neoantigen Cancer Vaccine Production Volume Share by Type (2018-2023)
-
Figure Northwest China Neoantigen Cancer Vaccine Production Volume Share by Type (2018-2023)
-
Table Northwest China Neoantigen Cancer Vaccine Sales Volume by Application (2018-2023)
-
Table Northwest China Neoantigen Cancer Vaccine Sales Volume Share by Application (2018-2023)
-
Figure Northwest China Neoantigen Cancer Vaccine Sales Volume Share by Application (2018-2023)
-
Table Geneos Therapeutics Company Profile
-
Table Geneos Therapeutics Neoantigen Cancer Vaccine Revenue, Price and Gross (2018-2023)
-
Table Roche Company Profile
-
Table Roche Neoantigen Cancer Vaccine Revenue, Price and Gross (2018-2023)
-
Table Gritstone Oncology Company Profile
-
Table Gritstone Oncology Neoantigen Cancer Vaccine Revenue, Price and Gross (2018-2023)
-
Table Vaccibody Company Profile
-
Table Vaccibody Neoantigen Cancer Vaccine Revenue, Price and Gross (2018-2023)
-
Table Merck Company Profile
-
Table Merck Neoantigen Cancer Vaccine Revenue, Price and Gross (2018-2023)
-
Table Genocea Company Profile
-
Table Genocea Neoantigen Cancer Vaccine Revenue, Price and Gross (2018-2023)
-
Table Brightpath Biotherapeutics Company Profile
-
Table Brightpath Biotherapeutics Neoantigen Cancer Vaccine Revenue, Price and Gross (2018-2023)
-
Table Agenus Company Profile
-
Table Agenus Neoantigen Cancer Vaccine Revenue, Price and Gross (2018-2023)
-
Table Medigene Company Profile
-
Table Medigene Neoantigen Cancer Vaccine Revenue, Price and Gross (2018-2023)
-
Table Advaxis Company Profile
-
Table Advaxis Neoantigen Cancer Vaccine Revenue, Price and Gross (2018-2023)
-
Table OSE Immunotherapeutics Company Profile
-
Table OSE Immunotherapeutics Neoantigen Cancer Vaccine Revenue, Price and Gross (2018-2023)
-
Table Nouscom Company Profile
-
Table Nouscom Neoantigen Cancer Vaccine Revenue, Price and Gross (2018-2023)
-
